Home/Pipeline/VAC2

VAC2

Non-small Cell Lung Cancer

Phase 1Active

Key Facts

Indication

Non-small Cell Lung Cancer

Phase

Phase 1

Status

Active

Company

Lineage Cell Therapeutics

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotech focused on developing novel, allogeneic cell therapies for unmet medical needs in neurology, oncology, and ophthalmology. Its core strategy is built on the proprietary AlloSCOPE™ platform, which enables the directed differentiation of pluripotent cells into scalable, 'off-the-shelf' therapeutic products. Recent achievements include a significant collaboration with Genentech for retinal programs and advancing its lead candidate, OPC1, for spinal cord injury. The company aims to validate its platform through clinical milestones and strategic partnerships to address large, underserved markets.

View full company profile

Therapeutic Areas

Neurology Ophthalmology Oncology

Other Non-small Cell Lung Cancer Drugs

Drug	Company	Phase	Status
CM24	Purple Biotech	Phase 2	Active
Pepinemab (VX15/2503)	Vaccinex	Phase 1b/2	Completed
GC-001	Genocury Biotech	Preclinical	Active
Immunomodulator Platform	OmniCyte	Research	Active
VisAcT (18F-AraG) Imaging in NSCLC	CellSight Technologies	Phase 2	Active
VNX-208	Vironexis Biotherapeutics	Preclinical	Active
AIC100	AffyImmune Therapeutics	Pre-clinical/Planned	Active
Lung (NSCLC) PD-L1	Mindpeak	Commercial	Active
Tiragolumab	Chugai Pharmaceutical	Phase III	Active
SHR-1701	Jiangsu Hengrui Medicine	Phase II/III	Active
Acasunlimab (DuoBody-PD-L1x4-1BB)	Genmab	Phase 2/3	Active